Auxano Biomedical seeks collaborative partners interested in commercializing unique wound diagnostics, antimicrobial technology and therapeutics in chronic wound healing and ophthalmic applications.
If you are interested in exploring a partnership with Auxano email: info@auxanobio.com.
Market Opportunities
The market for wound care products is expected to approach $5 billion over the next decade, driven largely by an aging population, an increase in diabetes, and new technology innovations. Diabetic ulcers and similar wounds are reaching epidemic proportions with over 2 million wounds worldwide requiring treatment. Diabetic ulcers ultimately lead to increased cost of care, amputation cost, and an extremely high death rate. Additionally, military wound care is a growing aspect of the market that will need to be addressed.
Auxano Biomedical is poised to meet the needs of the growing market by offering a tri-fold approach to wound care – wound diagnostics, infection control, and wound therapy.
Disorders targeted by our total wound care solutions includes:
- Chronic wounds – Diabetic, decubitis, and venous ulcers
- Ophthalmics – corneal ulcers and wounds related to vision corrective surgery
- Burns
Business Synergy
Auxano Biomedical is funded and managed by Emergent Technologies, Inc. (ETI), a venture capital firm with more than a dozen portfolio companies and technologies. ETI seeks scientific and business synergies within its portfolio of companies and partners, leveraging combined expertise to maximize opportunities for successful commercialization.
ETI has succeeded not only in gaining access to significant capital through four different affinity funds, but also in creating an efficient corporate structure that reduces costs of each company in the portfolio, leverages existing relationships and expertise, and successfully processes multiple opportunities without duplicating overhead and costs for each new endeavor.
